

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BROAD INTELLIGENCE INTERNATIONAL PHARMACEUTICAL HOLDINGS LIMITED

博智國際藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1149)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09(1) of the Listing Rules.

The Board wishes to inform the Shareholders and potential investors that it is preliminarily expected that the unaudited results of the Group for the six months ended 30 June 2009 may experience a loss.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the shares of the Company.

This announcement is made by Broad Intelligence International Pharmaceutical Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

It is preliminarily expected that the unaudited results of the Group for the six months ended 30 June 2009 may experience a loss.

The unaudited net loss of the Group for the six months ended 30 June 2009 amounted to approximately RMB50 million.

The board of directors of the Company (the “**Board**”) considers that the loss recorded was, among other things, primarily attributable to:–

1. the financial tsunami causing a sharp contraction of the market which in turn led to the decline in customer orders; and
2. deterioration of a raw material named “橄欖流浸膏” due to negligence of a staff member of the Group causing a stock loss of RMB18 million in June 2009.

This profit warning is based on the preliminary calculations by the Board in accordance with the management accounts of the Group, which has not been confirmed nor audited by the Company’s auditor. Shareholders of the Company and potential investors are advised to carefully read the interim report of the Company for the six months ended 30 June 2009, which is expected to be published on the website of the Company at www.broadintelligence.com.hk and on the website of Hong Kong Exchanges and Clearing Limited at www.hkex.com.hk before the end of September 2009.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board
Broad Intelligence International Pharmaceutical Holdings Limited
Zhong Houtai
Chairman

Hong Kong, 31st July 2009

As at the date of this announcement, the executive directors of the Company are Mr. Zhong Houtai, Mr. Zhong Houyao, Mr. Chong Hoi Fung, Mr. Sun Daquan and the independent non-executive directors of the Company are Mr. Cheung Chuen, Mr. Pei Renjiu and Mr. Li Kai Ming.